EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zhang, Zihe, Shi, Ruifeng, Liu, Minghui, Liu, Chao, Chen, Chen, Liu, Hongyu, Chen, Jun
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716470/
https://ncbi.nlm.nih.gov/pubmed/33276757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07667-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi